Year two of follow-up evaluation of a randomized, blind field trial of a commercial feline leukemia virus vaccine.
A blind randomized field trial of a commercial FeLV vaccine was conducted. Cats on study were vaccinated with either a commercial FeLV vaccine or a placebo, then housed with FeLV-positive cats in a ratio of approximately 2 study cats to 1 infected cat (results of the first 12 months of the study have been reported). All surviving placebo-treated and FeLV-vaccinated cats were re-vaccinated 1 year after initial exposure to FeLV-infected cats. Exposure continued for an additional 12 months, and the viremia status of the cats was monitored by immunofluorescent antibody (IFA) and ELISA testing at 4-month intervals. During the second year of observation, 1 additional FeLV-vaccinated cat had positive results of 2 consecutive ELISA tests, but remained IFA negative. Classifying this cat as persistently viremic reduced the estimate of the preventable fraction, but did not alter the conclusions drawn earlier, viz, that vaccination appreciably reduces the number of cats that become persistently viremic after long-term natural exposure.
Scarlett
J M
JM
Department of Clinical Sciences, New York State College of Veterinary Medicine, Cornell University, Ithaca 14853.
Pollock
R V
RV
D000818:Animals; D002415:Cats; D004797:Enzyme-Linked Immunosorbent Assay; D005069:Evaluation Studies as Topic; D005455:Fluorescent Antibody Technique; D005500:Follow-Up Studies; D007117:Immunization, Secondary / Q000662:veterinary; D005256:Leukemia Virus, Feline / Q000276:immunology*; D016582:Leukemia, Feline / Q000401:mortality / Q000517:prevention & control*; D015682:Retroviridae Proteins, Oncogenic; D012307:Risk Factors; D014611:Vaccination / Q000662:veterinary*; D014765:Viral Vaccines; D014766:Viremia / Q000401:mortality / Q000517:prevention & control / Q000662:veterinary*
D015682:Retroviridae Proteins, Oncogenic; D014765:Viral Vaccines; C045569:feline leukemia virus vaccine